LONDON, Aug. 03, 2022 (GLOBE NEWSWIRE) — Small Pharma Inc. (TSXV: DMT) (OTCQB: DMTTF) (the “ Company” or “Small Pharma”), a biotechnology company focused on short-acting psychedelic-assisted therapies for mental health conditions, today announces that as of July 19, 2022 it has been granted patent no. 3104072 by the Canadian Intellectual Property Office. This Canadian patent protects Composition…


Previous articleAlgernon Pharmaceuticals Invited to Present Phase 2 IPF and Chronic Cough Study Data at 9th American Cough Conference
Next articleMindMed to Participate in the Canaccord Genuity 42nd Annual Growth Conference